Title

Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions
A Two-way Crossover Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Nizatidine 300 mg Capsules in Healthy Human Subjects Under Non-fasting Conditions
  • Phase

    Phase 1
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    nizatidine ...
  • Study Participants

    26
The purpose of this study is to compare experimental evaluation of relative bioavailabilities in healthy, human subjects under non-fasting conditions.
Open label, balanced, randomized, two-treatment, two-period, two sequence, single dose, crossover, comparative oral bioavailability study in healthy, adult, male human subjects under non-fasting conditions.
Study Started
Jul 31
2004
Primary Completion
Sep 30
2004
Study Completion
Sep 30
2004
Last Update
Jul 14
2010
Estimate

Drug Nizatidine

Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited

  • Other names: Axid 300 mg Capsules

Drug Axid

Axid 300 mg Capsules of Reliant Pharmaceuticals, US

Nizatidine Experimental

Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited

Axid Active Comparator

Axid 300 mg Capsules of Reliant Pharmaceuticals, US

Criteria

Inclusion Criteria:

Healthy males between 18 and 55 years of age (inclusive) living in and around Ahmedabad city of western part of India.
Having a Body Mass Index (BMI) ≥ 18.0 kg/m2 (calculated as weight in kg/ height in m2).
Have no significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, ECG and X-ray recordings.
Able to communicate effectively with study personnel. Able to give consent for participation in the trial

Exclusion Criteria:

Known hypersensitivity or idiosyncratic reaction to nizatidine or other related drugs.
Any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal, or any other body system.
Ingestion of a medication at any time in 14 days before the start of the study. In any such case subject selection will be at the discretion of the Principal Investigator/Medical expert/co-investigator.
Any history or presence of asthma or nasal polyp.
A recent history of alcoholism (<2years) or of moderate (180 ml/day) alcohol use.
Smokers, who smoke more than 10 cigarettes/day or those who cannot refrain from smoking during study period.
The presence of clinically significant abnormal laboratory values during screening.
Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scan.
History of psychiatric disorders.
A history of difficulty with donating blood.
Donations of blood (1 unit or 450 ml) within 90 days prior to receiving the first dose of study medication. Note: Incase the blood loss is ≤ 200 L, subject may be dosed after completion of 60 days of blood donation).
A positive hepatitis screen including hepatitis B surface antigen, anti-HCV and anti-HAV antibodies.
A positive test result for HIV antibody and/or syphilis.
The receipt of an investigational product or participation in a drug research study within a period of 90 days prior to the first dose of study medication (Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study). (Note: If subject had participated in a study in which blood loss is ≤200 mL, subject can be dosed after completion of 60 days of previous study).
An unusual diet, for whatever reason (eg., low-sodium), for four weeks prior to receiving the study medication and throughout the subjects, participation in the study. In any such case subject will be at the discretion of the Principal Investigator/Medical expert/Co-investigator.
No Results Posted